Clinical Trial Detail

NCT ID NCT03230318
Title Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma (FIDES-01)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Basilea Pharmaceutica
Indications

intrahepatic cholangiocarcinoma

cholangiocarcinoma

Therapies

Derazantinib

Age Groups: senior adult

Additional content available in CKB BOOST